HIV-1 Phenotypic Susceptibility to Lopinavir (LPV) and Genotypic Analysis in LPV/r-Naive Subjects With Prior Protease Inhibitor Experience
- 1 August 2003
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 33 (4) , 439-447
- https://doi.org/10.1097/00126334-200308010-00004
Abstract
The relationship between phenotypic susceptibility to lopinavir (LPV) and genotypic pattern was investigated in LPV-naive, protease inhibitor (PI)-experienced subjects. Protease sequences of 100 HIV isolates with ascertained susceptibility (determined by Antivirogram) to LPV were analyzed (VircoGen). Two different thresholds (2.5- and 10-fold) were used for defining reduced susceptibility. Mutations were classified as LPV/r (the actual formulation of LPV that combines LPV with low-dose ritonavir) mutations according to the International AIDS Society-USA. Thirty-four isolates showed reduced LPV susceptibility (2.6- to 75.9-fold). Fold resistance to LPV correlated with the number of total and LPV/r mutations (Spearman coefficient = 0.62 and 0.74, respectively; P PKeywords
This publication has 17 references indexed in Scilit:
- Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacityAIDS, 2002
- A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapyAIDS, 2002
- Clinical utility of HIV-1 genotyping and expert advice: the Havana trialAIDS, 2002
- Identification of Genotypic Changes in Human Immunodeficiency Virus Protease That Correlate with Reduced Susceptibility to the Protease Inhibitor Lopinavir among Viral Isolates from Protease Inhibitor-Experienced PatientsJournal of Virology, 2001
- A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapyAIDS, 2000
- HIV-1 Genotypic Resistance Patterns Predict Response to saquinavir–ritonavir Therapy in Patients in Whom Previous Protease Inhibitor Therapy Had FailedAnnals of Internal Medicine, 1999
- Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trialThe Lancet, 1999
- Novel Four‐Drug Salvage Treatment Regimens after Failure of a Human Immunodeficiency Virus Type 1 Protease Inhibitor–Containing Regimen: Antiviral Activity and Correlation of Baseline Phenotypic Drug Susceptibility with Virologic OutcomeThe Journal of Infectious Diseases, 1999
- ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus ProteaseAntimicrobial Agents and Chemotherapy, 1998
- From the Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adultsJAMA, 1993